Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2021, and Provides Business Update
August 16, 2021 09:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2021, and Provides Business Update
May 17, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., May 17, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
Galectin Therapeutics to Present at 4th Global NASH Congress
April 27, 2021 09:28 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 27, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...
World-Renowned Neurosurgeon Dr. Ben Carson, Sr. Joins Galectin Therapeutics as Special Consultant to Accelerate and Enhance Development of Company’s Galectin-3 Inhibitor, Belapectin
April 19, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 19, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced it has engaged Dr....
Journal for ImmunoTherapy of Cancer Publishes Phase 1 Clinical Research Showing Belapectin, Galectin Therapeutics’ Galectin-3 Inhibitor, Enhances Tumor Response in Combination with Anti-PD-1 Therapy
April 13, 2021 19:01 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 13, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper...
Galectin Therapeutics Launches NAVIGATEnash.com, a Resource for Both Patients and Physicians about its Innovative NASH Cirrhosis Study
April 06, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., April 06, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of...
Galectin Therapeutics Reports Fiscal 2020 Financial Results and Provides Business Update
March 31, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 31, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and...
OncoImmunology Publishes Pre-clinical Research Showing Galectin Therapeutics’ Belapectin Galectin-3 Inhibitor Reduces Tumor Progression in Combination with Anti-OX40 Therapy
March 08, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 08, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that a paper...
Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
March 04, 2021 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., March 04, 2021 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Pol Boudes,...
Galectin Therapeutics, Inc. to Present at the 4th Annual Digital NASH Summit on December 17, 2020
December 11, 2020 08:00 ET
|
Galectin Therapeutics Inc.
NORCROSS, Ga., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Pol F. Boudes,...